The present invention relates to several novel 1-O-glycosylated sphingoid bases and to a production method thereof, as well as to uses of the 1-O-glycosylated sphingoid bases. Sphingoid bases carrying a vinylogous amide-type protecting group are used herein for the production of 1-O-glycosylated sphingoid bases. These vinylogous amide compounds enable an easy and effective production of 1-O-glycosylated sphingoid bases. ##STR00001##

The present disclosure is concerned with 2-pyrimidone compounds that are capable of inhibiting a viral infection and methods of treating alphavirus viral infections such as, for example, chikungunya, Eastern equine encephalitis (EEEV), Western equine encephalitis (WEEV), and Venezuelan equine encephalitis using these compounds. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

The invention provides compounds having the general formula I:

##STR00001##

and pharmaceutically acceptable salts thereof, wherein the variables R.sup.1, R.sup.2, R.sup.3 and R.sup.4 have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.

The invention provides compounds having the general formula I:

##STR00001##

and pharmaceutically acceptable salts thereof, wherein the variables R.sup.1, R.sup.2, R.sup.3 and R.sup.4 have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.

The invention provides compounds having the general formula I: and pharmaceutically acceptable salts thereof, wherein the variables R.sup.1, R.sup.2, R.sup.3 and R.sup.4 have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions. ##STR00001##

The invention provides compounds having the general formula I: and pharmaceutically acceptable salts thereof, wherein the variables R.sup.1, R.sup.2, R.sup.3 and R.sup.4 have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions. ##STR00001##

Compounds and compositions are provided that can inhibit microsomal prostaglandin E synthase-1 (mPGES-1). The compounds and compositions can reduce inflammation in a subject, such as inflammation caused by an inflammation disorder or symptoms thereof. Pharmaceutical compositions comprising the compound are also provided. Furthermore, methods are provided for reducing inflammation and/or inhibiting mPGES-1. The methods can comprise administering an effective amount of the composition to a subject.

A preparation method of a pyrimidinylthio-benzoate oxime ester compound and an application thereof are provided. The chemical structural formula of the pyrimidinylthio-benzoate compound is shown in the following formula (1). The preparation method includes step A: preparation of a substituted acetophenone oxime: taking hydroxylamine hydrochloride and a substituted acetophenone as a raw material, adding an alcohol as a solvent, and performing a reaction at 0° C.-80° C. for 1-5 hours under an alkaline condition to obtain the substituted acetophenone oxime; and step B: preparation of the compound: using 2-chloro-6-((4,6-dimethoxypyrimidin-2-yl)thio)benzoic acid and the substituted acetophenone oxime as a raw material, and performing a reaction under an action of an organic solvent, a dehydrating agent and a catalyst at 25° C. for 6-24 hours; after the reaction is completed, performing a suction filtration, and subjecting the filtrate to a decompression distillation and a recrystallization to obtain the compound. ##STR00001##

A preparation method of a pyrimidinylthio-benzoate oxime ester compound and an application thereof are provided. The chemical structural formula of the pyrimidinylthio-benzoate compound is shown in the following formula (1). The preparation method includes step A: preparation of a substituted acetophenone oxime: taking hydroxylamine hydrochloride and a substituted acetophenone as a raw material, adding an alcohol as a solvent, and performing a reaction at 0° C.-80° C. for 1-5 hours under an alkaline condition to obtain the substituted acetophenone oxime; and step B: preparation of the compound: using 2-chloro-6-((4,6-dimethoxypyrimidin-2-yl)thio)benzoic acid and the substituted acetophenone oxime as a raw material, and performing a reaction under an action of an organic solvent, a dehydrating agent and a catalyst at 25° C. for 6-24 hours; after the reaction is completed, performing a suction filtration, and subjecting the filtrate to a decompression distillation and a recrystallization to obtain the compound. ##STR00001##

The present invention relates to several novel 1-O-glycosylated sphingoid bases and to a production method thereof, as well as to uses of the 1-O-glycosylated sphingoid bases.

Sphingoid bases carrying a vinylogous amide-type protecting group are used herein for the production of 1-O-glycosylated sphingoid bases. These vinylogous amide compounds enable an easy and effective production of 1-O-glycosylated sphingoid bases.

##STR00001##